Relief of Discomfort

X39 Research

Studies Summary:

Key Findings from Studies Below...

  • Boosts a Special Peptide: The strongest studies showed that wearing the patch significantly increases levels of a natural copper-peptide in the blood (known as GHK-Cu). This peptide is heavily associated with tissue repair, anti-aging, and cellular health.

  • Massive Jump in Athletic Endurance: In a test with collegiate football players, those wearing the active patch increased their weightlifting stamina (bench press reps to failure) by 43% within just 10 minutes, vastly outperforming the placebo group.

  • Cellular Energy & Anti-Aging (Mitochondria): Testing on white blood cells showed that the patch helped trigger mitochondrial biogenesis—meaning it helped increase cellular energy production and made immune cells more resilient against inflammation and oxidative stress.

  • Amino Acid Rebalancing: The studies recorded noticeable shifts and increases in several essential amino acids and metabolic markers, suggesting improved internal chemistry and reduced inflammation.

  • Better Sleep and Sharper Memory: Participants in a controlled trial showed statistically significant improvements in short-term memory retention and reported noticeably better sleep quality within the first 24 to 48 hours of use.

  • Brain Wave Calming: Brain mapping (EEG) tests revealed that people who started with overactive, stressed brain activity experienced a measurable "calming" and balancing effect on their brain waves after a few weeks of use.

  • Relaxation and Biofield Balance: Monitoring showed physical signs of stress reduction, such as lower muscle tension, deeper breathing, and more balanced heart rate and organ energy readings.

Clinical Studies:

Study Title: Double-blind RCT of the LifeWave X39 Patch to determine GHK-Cu Production Levels

  • Study Type / Design: Double-blind, randomized controlled trial (RCT).

  • Sample Size & Demographics: 60 adult participants aged 40–80.

  • Intervention / Testing Period: Participants were computer-randomized into Group A or Group B and wore either active X39 phototherapy patches or placebo patches for a minimum of 8 hours daily over 7 days (placed at meridian point GV14). Blood draws were conducted at baseline, 24 hours, and 7 days.

  • Key Metrics Measured: Blood plasma concentration of copper tripeptide GHK-Cu analyzed via mass spectrometry (AB Sciex API4000 Qtrap LC-MS/MS).

  • Primary Results & Findings: The statistical evaluation demonstrated a statistically significant increase in blood GHK-Cu concentrations among participants wearing the active LifeWave X39 patch compared to the placebo control group over the 7-day period (\(p < 0.05\)).


Double-blind-RCT-of-the-LifeWave-X39-Patch-to-determine-GHK-Cu-Production-Levels.pdf


Study Title: Double Blind Clinical Trial of the LifeWave X39 Patch to Determine Metabolic and Physiological Effects

  • Study Type / Design: Double-blind, randomized controlled trial (RCT).

  • Sample Size & Demographics: 50 participants (26 in the Active group, 24 in the Control group; overall mean age 63, age range 40–81).

  • Intervention / Testing Period: Active X39 patches vs. placebo patches applied daily for 7 days at meridian points GV14 or CV6. Assessments were conducted at Day 1 (baseline), Day 2 (24 hours), and Day 7.

  • Key Metrics Measured: Salivary and urinary amino acid biosynthesis panels, WAIS-III digit span memory tests (short, mid, and long-term retention), Pittsburgh Sleep Quality Index (PSQI), Global Mood Scale (GMS), and physiological monitoring (blood pressure, respiration, muscle relaxation).

  • Primary Results & Findings: The Active X39 group achieved statistically significant improvements in WAIS-III short-term memory scores compared to the control group by Day 7 (\(p < 0.001\)). Active patch wearers also demonstrated significant improvements in sleep quality on the PSQI total score at Day 2 (\(p = 0.042\)), statistically significant elevations in 8 essential amino acids, deeper average respiration (\(p < 0.04\)), and improved muscle relaxation (\(p < 0.08\)) compared to controls.

Double-Blind-Clinical-Trial-of-the-LifeWave-X39-Patch-to-Determine-Metabolic-and-Physiological-Effects.pdf

Study Title: A Double Blind Placebo Controlled Study of the LifeWave Technology as it Relates to the Improvement of Strength Endurance in High Performance College Athletics

  • Study Type / Design: Double blind, placebo controlled trial.

  • Sample Size & Demographics: 25 collegiate football players from Troy State University (ages 18–22; split across Control, Placebo, and Active Test groups).

  • Intervention / Testing Period: Acute testing measuring flat bench press performance at a fixed weight of 225 lbs until failure. Comparative re testing was performed within 10 minutes of initial patch application (active non transdermal patch vs. water filled placebo patch vs. unpatched control).

  • Key Metrics Measured: Athletic strength endurance (maximum bench press repetition count to failure).

  • Primary Results & Findings: Participants wearing the active LifeWave patch achieved a 43.2% average increase in strength endurance (+2.6 repetitions average gain) within 10 minutes of patch application, significantly outperforming the Placebo group (13.8% increase) and Control group (8.9% increase). In addition, 85.7% of athletes in the active test group increased their repetition performance, compared to 62.5% in placebo and 70% in control.


Double-Blind-Placebo-Controlled-Study-of-the-LifeWave-Technology-as-it-Relates-to-the-Improvement-of-Strength-Endurance-in-High-Performance-College-Athletics.pdf


Study Title: Clinical Study on the X39 Patch Acute and Long Term Biological Effects (NIS Labs Report 171 003 / 206 001)

  • Study Type / Design: Double blind, placebo controlled crossover trial (acute phase) followed by an open label longitudinal study (4 week long term phase).

  • Sample Size & Demographics: 12 healthy adult participants (10 females, 2 males; age range 44.6 to 73.2, mean age ~63).

  • Intervention / Testing Period:

    • Acute Crossover: Baseline, 1 hour, and 2 hour blood draws on Day 0 and Day 7 comparing active X39 vs. placebo patch.

    • Long Term: Daily X39 patch wear over 4 weeks (tested at Baseline, Day 1, Week 1, and Week 4).

  • Key Metrics Measured: Immune cell flow cytometry, mitochondrial membrane potential, mitochondrial volume changes under ex vivo oxidative and inflammatory stress, pro and anti inflammatory cytokines, growth factors, C reactive protein, and questionnaires for energy, focus, and wellness.

  • Primary Results & Findings: Active X39 patch application produced increased mitochondrial membrane potential and mitochondrial volume resilience against oxidative and inflammatory stress in immune cells (lymphocytes and monocytes). Biological testing revealed elevated anti inflammatory cytokines and reduced pro inflammatory biomarkers. Subjective self reported energy levels showed a statistically significant increase by Week 4 (\(p = 0.0411\)).

Clinical-Study-on-the-X39-Patch-Acute-and-Long-Term-Biological-Effects-(NIS-Labs-Report-171-003-/-206-001).pdf

Study Title: Efficacy of LifeWave X 39 Phototherapy Patch in Elevating Biofield Energy and Organ Balance

  • Study Type / Design: Controlled pilot trial (non blinded experimental group vs. control group).

  • Sample Size & Demographics: 45 participants aged 40–65 (40 subjects in the experimental group, 5 subjects in the control group).

  • Intervention / Testing Period: Experimental group wore X39 patches for 12 hours daily over 6 weeks (applied at C7/GV14). Assessments occurred at Baseline, 3 weeks, and 6 weeks.

  • Key Metrics Measured: Biofield overall energy and organ balance/symmetry via Bio Well (Electro Photonic Imaging / Gas Discharge Visualization [EPI/GDV]), Biofield Viewer (BV pixel color analysis), and Multiscan Pro (vascular age, phase angle, wellness score).

  • Primary Results & Findings: The experimental X39 group demonstrated a statistically highly significant increase in overall biofield energy on Bio Well (\(p < 0.0001\)), a significant improvement in organ balance (\(p = 0.0030\)), and a significant increase in green pixel density on Biofield Viewer (\(p = 0.0111\)) over 6 weeks. The control group showed no statistically significant changes across any parameters.

Efficacy-of-LifeWave-X-39-Phototherapy-Patch-in-Elevating-Biofield-Energy-and-Organ-Balance.pdf

Study Title: Non invasive Phototherapy Patch Effect on Metabolism and Physiology / Metabolic and Physiological Effects of Lifewave X39 Patch

  • Study Type / Design: Open label, single arm pilot study (pre post uncontrolled convenience sample).

  • Sample Size & Demographics: 15 adult participants (10 females / 67%, 5 males / 33%; mean age \(61.9 \pm 9.3\) years).

  • Intervention / Testing Period: X39 patches worn daily for 7 days (placed at GV14 or CV6). Data collected at baseline (Day 1), Day 2 (24 hours), and Day 7.

  • Key Metrics Measured: Salivary/urinary amino acids and neurotransmitter panels (Sabre Sciences), physiological suite measures (HRV via EKG/BVP, EMG muscle tension, skin conductance, temperature, respiration rate), salivary Cortisol and DHEAS Area Under the Curve (AUC), and questionnaires (WAIS III memory, PSQI sleep quality, Marlowe Crowne, POMS, McGill pain, AIOS VAS).

  • Primary Results & Findings: Demonstrates a statistically significant reduction in EMG muscle tension (\(p = 0.0035\) across epochs), significant shifts in autonomic heart rate variability (HRV) (decreases in BVP NN50, RMSSD, and SDNN, \(p < 0.01\)), significant improvement in sleep quality on the modified PSQI at Day 7 (\(p = 0.0522\)), and 17 significant changes in amino acids (e.g., Histidine \(p = 0.0026\), Glutamate \(p = 0.0475\)). No significant changes were observed in salivary Cortisol or DHEAS AUC.

Non-invasive-Phototherapy-Patch-Effect-on-Metabolism-and-Physiology-/-Metabolic-and-Physiological-Effects-of-Lifewave-X39-Patch.pdf

Study Title: Pilot Study on the Effects of LifeWave X39 Patch on Brain Wave Topography, Reaction Time, and Cognition (Psy Tek Labs Report)

  • Study Type / Design: Open label, single arm pilot study (pre post uncontrolled convenience sample).

  • Sample Size & Demographics: 12 healthy adult participants (10 females, 2 males; age range 56–73).

  • Intervention / Testing Period: Patches applied daily at GV14 or CV6 over a 6 week period, with evaluation sessions at Baseline, 3 weeks, and 6 weeks.

  • Key Metrics Measured: Quantitative EEG (qEEG topographic brain amplitude and coherence maps, CZ Theta/Beta ratio, F3/F4 Alpha asymmetry), Audio P300 event related potential delay/voltage, Physical Reaction Time (ms), mood (BMIS), and self reported well being (AIOS VAS).

  • Primary Results & Findings: Showed a statistically significant reduction in Audio P300 voltage at 3 weeks (\(p = 0.004\)) and 6 weeks (\(p = 0.017\)), along with reaction time shifts at 3 weeks (\(p = 0.016\)). Quantitative EEG coherence mapping revealed that participants presenting with baseline hyperactive brain activity experienced significant calming and normalization of brain coherence after 3 weeks of patch wear.


Pilot Study on the Effects of LifeWave X39 Patch on Brain Wave Topography, Reaction Time, and Cognition (Psy Tek Labs Report).pdf

Study Title: Changes in Tripeptides Produced By the LifeWave X39 Patch

  • Study Type / Design: Open label, single arm pilot study (pre post sample of convenience).

  • Sample Size & Demographics: 10 adult participants (4 men, 6 women; mean age 64.2, age range 41–73).

  • Intervention / Testing Period: X39 patch placed at CV6 or GV14 for 7 days, with blood plasma collected at baseline, 24 hours, and 7 days.

  • Key Metrics Measured: Blood plasma concentrations of GHK and GHK Cu tripeptides quantified via AB Sciex API4000 Qtrap mass spectrometry.

  • Primary Results & Findings: Showed a statistically significant elevation of plasma GHK within 24 hours (mean increase 9.5 ng/ml, \(p = 0.0098\)) and a statistically significant elevation of GHK Cu by Day 7 (mean increase 4.2 ng/ml, \(p = 0.0137\)).


Changes in Tripeptides Produced By the LifeWave X39 Patch.pdf